To demonstrate that the addition of ianalumab to standard first-line corticosteroids prolongs Time to Treatment Failure compared to Corticosteroids alone in participants with primary ITP. ITP means immune thrombocytopenia. Time from randomization to treatment failure which is defined as Platelet count below 30G/L after 8 weeks from randomization. Need for a rescue treatment after 8 weeks from randomization. Start of a second-line therapy or death. Complete response rate at each time point which is defined as the proportion of participants with any platelet count of at least 100 G/L in the absence of rescue treatment or new ITP treatment. Response rate at each timepoint which is defined as the proportion of participants with any platelet count of at least 50 G/L in the absence of rescue treatment or new ITP treatment.

Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).

see protocol see protocol see protocol

The purpose of this research study is to determine whether the study drug, Solriamfetol, is safe and effective for the treatment of Major Depressive Disorder (MDD). Solriamfetol, also called Sunosi®, is approved by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for people who have excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea (OSA).

The dupilumab clinical program in EoE has provided evidence that long-term suppression of IL-4 and IL-13 could lead to progressive improvement in fibrostenosis. . There is a need for longer term assessments with comprehensive functional, histological, molecular, clinical, and endoscopic assessments to characterize the risk of fibrotic progression as well the potential for reversal with dupilumab.